- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: MK-0787 | MK0787 | Primaxin® (imipenem + cilastatin) | Recarbrio® (imipenem + cilastatin + relebactam).
imipenem is an approved drug (FDA (1985), UK (1988))
Compound class: Synthetic organic
Comment: Imipenem is a broad-spectrum, semi-synthetic, intravenous β-lactam carbapenem derived from thienamycin.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Imipenem was first approved by the FDA in November 1985 as a component of fixed-dose combination product Primaxin (imipenem + cilastatin). It is also available in a triple combination with cilastatin and relebactam (Recarbrio).|